LBP-029-YI Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC
Marta Piqué‐Gili, Anna Vila-Escoda, Marta Casado-Peláez, Roser Pinyol, Ana Hernández de Sande, Verónica Dávalos, Albert Gris‐Oliver, Carla Montironi, Judit Peix, Eduard Porta‐Pardo, Daniela Grases, Sarah Cappuyns, Ezequiel Mauro, Guillem Cano-Segarra, Igor Figueiredo, Giorgio Ioannou, Edgar Gonzalez‐Kozlova, Tim Meyer, Anja Lachenmayer, Jens U. Marquardt, Helen L. Reeves, Julien Edeline, Fabian Finkelmeier, Jörg Trojan, Jean–Frédéric Blanc, Richard Hubner, Matthias Pinter, Tom Luedde, Arndt Vogel, Sacha Gnjatic, Daniela Sia, Vincenzo Mazzaferro, Jeroen Dekervel, Manel Esteller, Josep M. Llovet (2025). LBP-029-YI Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC. , 82, DOI: https://doi.org/10.1016/s0168-8278(25)00447-7.
